Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soluble ST2 correlation with disease activity in moderate to severe ulcerative colitis patients treated with golimumab
2014-003262-25Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in autoimmune colitis, sponsored by Merck & Co. Primary endpoint: Endoscopic disease activity at week 6. Started Nov 2014; status: completed.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2014-003262-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003262-25.